Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: May 20, 2011
Last updated: November 1, 2016
Last verified: November 2016
This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.

Non-Squamous Non-Small Cell Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational, Epidemiological and Non Interventional Study Evaluating the Evolution of Lung Cancer Related Symptoms and Its Correlation With Disease Control Rate in Patients With Non-Small Cell Lung Cancer (NSCLC) Initiating First-line Treatment With Platinum Based Standard Chemotherapy.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Change in lung cancer related symptoms (LCSS questionnaire) [ Time Frame: up to approximately 6 months (4-6 cycles of chemotherapy) ]
  • Correlation of lung cancer related symptoms and disease control rate (complete response, partial response, stable disease according to RECIST criteria) [ Time Frame: approximately 2 years ]

Secondary Outcome Measures:
  • Frequency/severity of lung cancer related symptoms (LCSS questionnaire) [ Time Frame: approximately 2 years ]

Enrollment: 156
Study Start Date: May 2011
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Non-small cell lung cancer patients initiating treatment with platinum-based chemotherapy +/- bevacizumab

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Histologically or cytologically confirmed non-small cell lung cancer
  • Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab

Exclusion Criteria:

  • Contraindications to the use of platinum-based chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01358942

Vitoria, Alava, Spain, 01009
Alcoy, Alicante, Spain, 03804
Elche, Alicante, Spain, 03203
Elda, Alicante, Spain, 03600
Oviedo, Asturias, Spain, 33011
Jerez de La Frontera, Cadiz, Spain, 11407
San Sebastian, Guipuzcoa, Spain, 20080
Mahon, Islas Baleares, Spain, 07703
Palma de Mallorca, Islas Baleares, Spain, 07012
Palma de Mallorca, Islas Baleares, Spain, 07014
Logroño, La Rioja, Spain, 26006
Alcala de Henares, Madrid, Spain, 28805
Melilla, Malaga, Spain, 52005
Pamplona, Navarra, Spain, 31006
Pamplona, Navarra, Spain, 31008
Tudela, Navarra, Spain, 46010
Sagunto, Valencia, Spain, 46520
Xativa, Valencia, Spain, 46800
Bilbao, Vizcaya, Spain, 48013
Alicante, Spain, 3010
Barcelona, Spain, 08006
Barcelona, Spain, 08017
Barcelona, Spain, 08906
Castellon, Spain, 12002
Jaen, Spain, 23007
Madrid, Spain, 28031
Madrid, Spain, 28033
Madrid, Spain, 28040
Madrid, Spain, 28041
Madrid, Spain, 28046
Madrid, Spain, 28050
Malaga, Spain, 29010
Navarra, Spain, 31008
Pontevedra, Spain, 36002
Segovia, Spain, 40002
Valencia, Spain, 46015
Valencia, Spain, 46017
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01358942     History of Changes
Other Study ID Numbers: ML25493
Study First Received: May 20, 2011
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on May 23, 2017